{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:41:12Z","timestamp":1793263272802,"version":"4.5.0"},"reference-count":185,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021096","name":"George Institute for Global Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ekir.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T21:56:37Z","timestamp":1726178197000},"page":"3553-3569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Scoping Review of Economic Analyses of Rare Kidney Diseases"],"prefix":"10.1016","volume":"9","author":[{"given":"Blake","family":"Angell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gadsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeoma I.","family":"Ulasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnivo","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Palagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.09.004_bib1","doi-asserted-by":"crossref","first-page":"c194","DOI":"10.1159\/000339785","article-title":"Orphan kidney diseases","volume":"120","author":"Soliman","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2024.09.004_bib2","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/S0140-6736(14)60659-0","article-title":"Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association. Rare inherited kidney diseases: challenges, opportunities, and perspectives","volume":"383","author":"Devuyst","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.09.004_bib3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.kint.2017.06.018","article-title":"Common elements in rare kidney diseases: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"92","author":"Aym\u00e9","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.09.004_bib4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2215\/CJN.0000000000000220","article-title":"A\u00a0policy call to address rare kidney disease in health care plans","volume":"18","author":"Vanholder","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.004_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.09.004_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2215\/CJN.08150718","article-title":"An international analysis of dialysis services reimbursement","volume":"14","author":"van der Tol","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.004_bib7","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1017\/S0266462321000337","article-title":"Examining the impact of different country processes for appraising rare disease treatments: a case study analysis","volume":"37","author":"Whittal","year":"2021","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ekir.2024.09.004_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40271-022-00598-4","article-title":"Improving interpretation of evidence relating to quality of life in health technology assessments of rare disease treatments","volume":"16","author":"Nicod","year":"2023","journal-title":"Patient"},{"key":"10.1016\/j.ekir.2024.09.004_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","article-title":"Socio-economic burden of rare diseases: a systematic review of cost of illness evidence","volume":"119","author":"Angelis","year":"2015","journal-title":"Health Policy"},{"key":"10.1016\/j.ekir.2024.09.004_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-021-01815-3","article-title":"Cost-of-illness studies in rare diseases: a scoping review","volume":"16","author":"Garc\u00eda-P\u00e9rez","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s40273-023-01308-0","article-title":"Are we capturing the socioeconomic burden of rare genetic disease? A scoping review of economic evaluations and cost-of-illness studies","volume":"41","author":"Marshall","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ekir.2024.09.004_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ekir.2024.09.004_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2024.09.004_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"10.1016\/j.ekir.2024.09.004_bib22","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/0961203315584812","article-title":"Total cost and cost predictors in systemic lupus erythematosus\u00a0\u22128-years follow-up of a Swedish inception cohort","volume":"24","author":"J\u00f6nsen","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.semarthrit.2015.11.013","article-title":"Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts","volume":"45","author":"J\u00f6nsen","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2024.09.004_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s13023-021-01966-3","article-title":"Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework","volume":"16","author":"Connolly","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0961203316676641","article-title":"Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs","volume":"26","author":"Anandarajah","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/09612033211073670","article-title":"An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States","volume":"31","author":"Bell","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/09612033221146093","article-title":"The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States","volume":"32","author":"Bell","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib28","article-title":"Healthcare resource utilization and associated costs in patients with systemic lupus erythematosus diagnosed with lupus nephritis","volume":"15","author":"Bell","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ekir.2024.09.004_bib29","first-page":"1249","article-title":"Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States","volume":"27","author":"Bell","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107494","article-title":"Economic burden associated with tuberous sclerosis complex in patients with epilepsy","volume":"112","author":"Betts","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ekir.2024.09.004_bib31","doi-asserted-by":"crossref","first-page":"347.e17","DOI":"10.1016\/j.urolonc.2022.04.007","article-title":"Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: a longitudinal case-control study using the SEER-Medicare data","volume":"40","author":"Bhandari","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib32","first-page":"537","article-title":"Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin","volume":"23","author":"Blaylock","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12894-022-01160-y","article-title":"Renal cell carcinoma: the population, real world, and cost-of-illness","volume":"22","author":"Buja","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.ekir.2024.09.004_bib34","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00296-016-3551-y","article-title":"Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study","volume":"36","author":"Chiu","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ekir.2024.09.004_bib35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0961203314524849","article-title":"Costs of illness and quality of life in patients with systemic lupus erythematosus in South Korea","volume":"23","author":"Cho","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib36","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/j.clgc.2018.10.016","article-title":"Economic burden of metastatic clear-cell renal cell carcinoma for French patients treated with targeted therapies","volume":"17","author":"Cholley","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/acr.22452","article-title":"Costs associated with severe and nonsevere systemic lupus erythematosus in Canada","volume":"67","author":"Clarke","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ekir.2024.09.004_bib38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.semarthrit.2020.04.014","article-title":"The economic burden of systemic lupus erythematosus in commercially- and Medicaid-insured populations in the United States","volume":"50","author":"Clarke","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2024.09.004_bib39","first-page":"36","article-title":"Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States","volume":"29","author":"Dall\u2019Era","year":"2023","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/annrheumdis-2012-202443","article-title":"Annual direct medical cost of active systemic lupus erythematosus in five European countries","volume":"73","author":"Doria","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12913-017-2513-8","article-title":"Real-world costs of autosomal dominant polycystic kidney disease in the Nordics","volume":"17","author":"Eriksson","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/epi4.12636","article-title":"Epidemiology and disease burden of tuberous sclerosis complex in France: a population-based study based on national health insurance data","volume":"7","author":"Fagnani","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ekir.2024.09.004_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251409","article-title":"Direct health system costs for systemic lupus erythematosus patients in Alberta, Canada","volume":"16","author":"Fatoye","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.09.004_bib44","first-page":"500","article-title":"Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population","volume":"16","author":"Furst","year":"2013","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib45","first-page":"193","article-title":"Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage","volume":"24","author":"Gagnon-Sanschagrin","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib46","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.clgc.2014.08.013","article-title":"Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States","volume":"13","author":"Geynisman","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib47","first-page":"1300","article-title":"Economic burden of selected adverse events in patients aged\u00a0\u226565 years with metastatic renal cell carcinoma","volume":"16","author":"Hagiwara","year":"2013","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000503","article-title":"Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015","volume":"8","author":"Jiang","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ekir.2024.09.004_bib49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clgc.2022.12.008","article-title":"Epidemiology and economic burden of von Hippel-Lindau disease-associated renal cell carcinoma in the United States","volume":"21","author":"Jonasch","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/808391","article-title":"Healthcare utilization and costs of systemic lupus erythematosus in Medicaid","volume":"2013","author":"Kan","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ekir.2024.09.004_bib51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12931-017-0543-8","article-title":"Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients","volume":"18","author":"Karl","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1586\/14737167.2015.1065733","article-title":"The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland","volume":"15","author":"Kawalec","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0961203313517407","article-title":"The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease","volume":"23","author":"Khamashta","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib54","first-page":"1087","article-title":"The economic burden of tuberous sclerosis complex in the UK: a retrospective cohort study in the Clinical Practice Research Datalink","volume":"19","author":"Kingswood","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/resp.14234","article-title":"Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: a nationwide population-based cohort study","volume":"27","author":"Knarborg","year":"2022","journal-title":"Respirology"},{"key":"10.1016\/j.ekir.2024.09.004_bib56","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.4103\/0366-6999.216412","article-title":"Analysis on inpatient health expenditures of renal cell carcinoma in a Grade-A Tertiary Hospital in Beijing","volume":"130","author":"Liu","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ekir.2024.09.004_bib57","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.clinthera.2021.06.009","article-title":"Retrospective analysis of disease severity, health care resource utilization, and costs among patients initiating Belimumab for the treatment of systemic lupus erythematosus","volume":"43","author":"Lokhandwala","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.ekir.2024.09.004_bib58","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/acr.22167","article-title":"Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain","volume":"66","author":"L\u00f3pez-Bastida","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ekir.2024.09.004_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162864","article-title":"In-hospital economic burden of metastatic renal cell carcinoma in France in the era of targeted therapies: analysis of the French National Hospital database from 2008 to 2013","volume":"11","author":"Maroun","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.09.004_bib60","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/0961203318768882","article-title":"Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: a general population-based study","volume":"27","author":"McCormick","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib61","first-page":"786","article-title":"Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study","volume":"23","author":"Miyazaki","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008503","article-title":"Quantifying the direct public health care cost of systemic sclerosis: A comprehensive data linkage study","volume":"96","author":"Morrisroe","year":"2017","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ekir.2024.09.004_bib63","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10545-018-0178-z","article-title":"Medical and financial burden of acute intermittent porphyria","volume":"41","author":"Neeleman","year":"2018","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib64","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/1756-185X.14433","article-title":"Direct and indirect health-related costs of systemic sclerosis in New Zealand","volume":"25","author":"Padala","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib65","first-page":"967","article-title":"Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database","volume":"18","author":"Petri","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib66","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/rheumatology\/key150","article-title":"Mortality, length of stay and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample","volume":"57","author":"Ram Poudel","year":"2018","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.ekir.2024.09.004_bib67","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2022AO6553","article-title":"Increase in direct costs for health systems due to lupus nephritis: the case of Colombia","volume":"20","author":"Prada","year":"2022","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"10.1016\/j.ekir.2024.09.004_bib68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s13023-021-01963-6","article-title":"Economic burden and health related quality of life of ultra-rare Gaucher disease in China","volume":"16","author":"Qi","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib69","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2217\/cer-2018-0062","article-title":"Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis","volume":"7","author":"Quock","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/cer-2017-0100","article-title":"Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data","volume":"7","author":"Quock","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib71","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13023-020-01523-4","article-title":"Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States","volume":"15","author":"Sieluk","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib72","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2014.12.017","article-title":"Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2","volume":"68","author":"Soerensen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ekir.2024.09.004_bib73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.seizure.2021.06.027","article-title":"Epidemiology, healthcare resource use, and mortality in patients with tuberous sclerosis complex: a population-based study on German health insurance data","volume":"91","author":"Strzelczyk","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.ekir.2024.09.004_bib74","first-page":"349","article-title":"Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study","volume":"18","author":"Sun","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib75","first-page":"1149","article-title":"Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data","volume":"28","author":"Sundaram","year":"2022","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib76","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/1756-185X.13363","article-title":"Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study","volume":"21","author":"Tanaka","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib77","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/acr.21815","article-title":"Inpatient health care utilization by children and adolescents with systemic lupus erythematosus and kidney involvement","volume":"65","author":"Tanzer","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ekir.2024.09.004_bib78","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.semarthrit.2019.07.009","article-title":"Inpatient burden and association with comorbidities of polyarteritis nodosa: national Inpatient Sample 2014","volume":"50","author":"Ungprasert","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2024.09.004_bib79","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-017-0628-2","article-title":"Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting pazopanib or sunitinib treatment: a retrospective Medicare claims analysis","volume":"34","author":"Vogelzang","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2024.09.004_bib80","article-title":"Annual direct cost and Cost-Drivers of systemic lupus erythematosus: a multi-center cross-sectional study from CSTAR registry","volume":"20","author":"Wang","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ekir.2024.09.004_bib81","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/03007995.2021.1940907","article-title":"Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a Medicaid population","volume":"37","author":"Yang","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2024.09.004_bib82","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3899\/jrheum.180445","article-title":"Economic burden among commercially insured patients with systemic sclerosis in the United States","volume":"46","author":"Zhou","year":"2019","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ekir.2024.09.004_bib83","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00296-015-3344-8","article-title":"Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus","volume":"35","author":"Park","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ekir.2024.09.004_bib84","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2217\/cer-2022-0141","article-title":"Diagnostic amyloid light chain amyloidosis hospitalizations associated with high acuity and cost: analysis of the Premier Healthcare Database","volume":"11","author":"D\u2019Souza","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib85","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13023-020-01517-2","article-title":"Prevalence, mortality and healthcare economic burden of tuberous sclerosis in Hong Kong: a population-based retrospective cohort study (1995-2018)","volume":"15","author":"Chu","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib86","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.semarthrit.2019.11.007","article-title":"An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea","volume":"50","author":"Kim","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2024.09.004_bib87","first-page":"706","article-title":"Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura","volume":"24","author":"Pollissard","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib88","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/WNO.0000000000001220","article-title":"The cost-effectiveness of tocilizumab (Actemra) therapy in giant cell arteritis","volume":"41","author":"Jogimahanti","year":"2021","journal-title":"J\u00a0Neuroophthalmol"},{"key":"10.1016\/j.ekir.2024.09.004_bib89","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/imt-2019-0199","article-title":"Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma","volume":"12","author":"Ambavane","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ekir.2024.09.004_bib90","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.3747\/co.23.2244","article-title":"Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada","volume":"23","author":"Amdahl","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175920","article-title":"Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom","volume":"12","author":"Amdahl","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.09.004_bib92","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1080\/03007995.2020.1799771","article-title":"Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma","volume":"36","author":"Bensimon","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2024.09.004_bib93","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s41669-023-00395-1","article-title":"Cost-Effectiveness of Nivolumab Plus ipilimumab for the First-Line Treatment of Intermediate\/Poor-Risk Advanced and\/or Metastatic Renal Cell Carcinoma in Switzerland","volume":"7","author":"\u00c7akar","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.ekir.2024.09.004_bib94","first-page":"1579","article-title":"An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy","volume":"23","author":"Capri","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/COC.0000000000000884","article-title":"A\u00a0cost-effectiveness analysis comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and sunitinib for treatment of advanced renal cell carcinoma","volume":"45","author":"Chan","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib96","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40261-019-00820-6","article-title":"Cost-effectiveness analysis of pembrolizumab plus axitinib versus sunitinib in first-line advanced renal cell carcinoma in China","volume":"39","author":"Chen","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ekir.2024.09.004_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177364","article-title":"Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: a real-world cost-effectiveness analysis of sequential first- and second-line treatments","volume":"12","author":"De Groot","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.09.004_bib98","first-page":"46","article-title":"Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States","volume":"21","author":"Delea","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215761","article-title":"Treatment sequences for advanced renal cell carcinoma: a health economic assessment","volume":"14","author":"Deniz","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.09.004_bib100","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1002\/ONCO.13522","article-title":"Cost-effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal cell carcinoma in the U.S","volume":"26","author":"Ding","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ekir.2024.09.004_bib101","article-title":"Cost-effectiveness of the first line treatment options for metastatic renal cell carcinoma in India","volume":"9","author":"Gupta","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib102","first-page":"893","article-title":"Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price","volume":"24","author":"Kim","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib103","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40258-021-00640-w","article-title":"Cost-effectiveness and value of information of cabozantinib treatment for patients with advanced renal cell carcinoma after failure of prior therapy in South Korea","volume":"19","author":"Kim","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ekir.2024.09.004_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.736860","article-title":"Cost-effectiveness of nivolumab plus cabozantinib versus sunitinib as a first-line treatment for advanced renal cell carcinoma in the United States","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2024.09.004_bib105","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1007\/s12325-021-01926-0","article-title":"Cost-effectiveness analysis of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in the United States","volume":"38","author":"Liao","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2024.09.004_bib106","article-title":"Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.09.004_bib107","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3389\/fphar.2020.00619","article-title":"A\u00a0cost-effectiveness analysis: first-line avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"11","author":"Lu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2024.09.004_bib108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.euo.2023.01.011","article-title":"Cost effectiveness of treatment sequences in advanced renal cell carcinoma","volume":"6","author":"Mason","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib109","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-018-0095-8","article-title":"Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States","volume":"7","author":"McCrea","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/CEOR.S159833","article-title":"Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England","volume":"10","author":"Meng","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib111","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.clinthera.2013.10.004","article-title":"Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia","volume":"35","author":"Mihajlovi\u0107","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.ekir.2024.09.004_bib112","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40261-018-0705-6","article-title":"Cost-utility of sunitinib versus pazopanib in metastatic renal cell carcinoma in Canada using real-world evidence","volume":"38","author":"Nazha","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ekir.2024.09.004_bib113","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1517\/14656566.2015.1039982","article-title":"Cost-effectiveness analysis of axitinib through a probabilistic decision model","volume":"16","author":"Petrou","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ekir.2024.09.004_bib114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14737167.2014.873703","article-title":"Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus","volume":"14","author":"Petrou","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1017\/S0266462319000059","article-title":"Cost-Effectiveness Analysis of sunitinib versus interferon-Alfa for First-Line Treatment of Advanced and\/or Metastatic Renal Cell Carcinoma in Singapore","volume":"35","author":"Pruis","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ekir.2024.09.004_bib116","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/COC.0000000000000451","article-title":"Nivolumab in the treatment of metastatic renal cell carcinoma: a cost-utility analysis","volume":"41","author":"Raphael","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib117","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2147\/CMAR.S188849","article-title":"Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis","volume":"11","author":"Redig","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib118","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1634\/theoncologist.2018-0656","article-title":"A\u00a0cost-effectiveness analysis of nivolumab and ipilimumab versus sunitinib in first-line intermediate- to poor-risk advanced renal cell carcinoma","volume":"24","author":"Reinhorn","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ekir.2024.09.004_bib119","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.eururo.2017.07.041","article-title":"Cost effectiveness of nivolumab in advanced renal cell carcinoma","volume":"73","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ekir.2024.09.004_bib120","first-page":"89","article-title":"Cost-effectiveness of adjuvant pembrolizumab after nephrectomy for high-risk renal cell carcinoma: insights for patient selection from a markov model","volume":"209","author":"Sharma","year":"2023","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ekir.2024.09.004_bib121","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clgc.2021.01.009","article-title":"A\u00a0cost-effectiveness analysis of nivolumab plus ipilimumab versus pembrolizumab plus axitinib and versus avelumab plus axitinib in first-line treatment of advanced renal cell carcinoma","volume":"19","author":"Shay","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib122","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14737167.2019.1580572","article-title":"Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison","volume":"19","author":"Vargas","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib123","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib124","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1002\/cncr.30666","article-title":"Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives","volume":"123","author":"Wan","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib125","article-title":"Cost-effectiveness of lenvatinib plus pembrolizumab or everolimus as first-line treatment of advanced renal cell carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ekir.2024.09.004_bib126","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16144","article-title":"Cost-effectiveness of pembrolizumab plus axitinib vs nivolumab plus ipilimumab as first-line treatment of advanced renal cell carcinoma in the US","volume":"3","author":"Watson","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2024.09.004_bib127","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"Wu","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib128","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/imt-2020-0034","article-title":"Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma","volume":"12","author":"Zhu","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ekir.2024.09.004_bib129","doi-asserted-by":"crossref","first-page":"417.e1","DOI":"10.1016\/j.clgc.2022.11.014","article-title":"First-Line lenvatinib Plus Pembrolizumab or everolimus versus sunitinib for Advanced Renal Cell Carcinoma: a United States-Based Cost-Effectiveness Analysis","volume":"21","author":"Zhu","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib130","first-page":"715","article-title":"Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease","volume":"20","author":"Clark","year":"2017","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib131","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","article-title":"Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease","volume":"159","author":"Erickson","year":"2013","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ekir.2024.09.004_bib132","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-8-29","article-title":"Cost-effectiveness of enzyme replacement therapy for Fabry disease","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.ekir.2024.09.004_bib133","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-9-51","article-title":"Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease","author":"van Dussen","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20031917","article-title":"Cost Consequence Analysis of Belimumab versus Standard of Care for the Management of systemic lupus erythematosus in Saudi Arabia: a Retrospective Cohort Study","volume":"20","author":"Alsuwayegh","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ekir.2024.09.004_bib135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12325-022-02332-w","article-title":"Cost-effectiveness of Acthar gel versus standard of care for the treatment of exacerbations in moderate-to-severe systemic lupus erythematosus","volume":"40","author":"Bindra","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2024.09.004_bib136","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40273-022-01166-2","article-title":"Belimumab for treating active autoantibody-positive systemic lupus erythematosus: an evidence review group perspective of a NICE single technology appraisal","volume":"40","author":"Otten","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ekir.2024.09.004_bib137","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/704207","article-title":"Health technology assessment of Belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus","volume":"2014","author":"Specchia","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ekir.2024.09.004_bib138","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/03007995.2021.1904861","article-title":"Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia","volume":"37","author":"Vandewalle","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2024.09.004_bib139","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.clgc.2022.03.011","article-title":"Cost effectiveness analysis of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) for early stage renal cell carcinoma (RCC)","volume":"20","author":"Donovan","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib140","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jpeds.2015.08.068","article-title":"A\u00a0cost-effectiveness analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in The Republic of Angola","volume":"167","author":"McGann","year":"2015","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ekir.2024.09.004_bib141","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.euf.2019.09.002","article-title":"A\u00a0decision analysis evaluating screening for kidney cancer using focused renal ultrasound","volume":"7","author":"Rossi","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ekir.2024.09.004_bib142","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/jmedgenet-2021-108215","article-title":"Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC)","volume":"60","author":"Thompson","year":"2023","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ekir.2024.09.004_bib143","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/CCI.20.00124","article-title":"Microsimulation model for evaluating the cost-effectiveness of surveillance in BAP1 pathogenic variant carriers","volume":"5","author":"Walpole","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.ekir.2024.09.004_bib144","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.kint.2017.08.016","article-title":"Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective","volume":"93","author":"Flahault","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.09.004_bib145","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1148\/radiol.2019181399","article-title":"MR angiography screening and surveillance for intracranial aneurysms in autosomal dominant polycystic kidney disease: a cost-effectiveness analysis","volume":"291","author":"Malhotra","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2024.09.004_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2022.103485","article-title":"Added value of Joint ENT-Rheumatology clinic in the management of ANCA-associated vasculitis: one year\u2019s experience","volume":"43","author":"Stavrakas","year":"2022","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ekir.2024.09.004_bib147","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11845-017-1625-9","article-title":"Auditing the frequency and the clinical and economic impact of testing for Fabry disease in patients under the age of 70 with a stroke admitted to Saint Vincent\u2019s University Hospital over a 6-month period","volume":"187","author":"Lambe","year":"2018","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.ekir.2024.09.004_bib148","first-page":"493","article-title":"Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010","volume":"23","author":"Hatam","year":"2013","journal-title":"Iran J Pediatr: shiraz, iran: shiraz university of medical sciences"},{"key":"10.1016\/j.ekir.2024.09.004_bib149","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.ajkd.2012.06.004","article-title":"Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children","volume":"61","author":"Laskin","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib150","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/0961203319851559","article-title":"Cost-effectiveness of a peer mentoring intervention to improve disease self-management practices and self-efficacy among African American women with systemic lupus erythematosus: analysis of the Peer Approaches to Lupus Self-management (PALS) pilot study","volume":"28","author":"Williams","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib151","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yebeh.2016.07.034","article-title":"Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis Complex","volume":"63","author":"Fallah","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ekir.2024.09.004_bib152","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MBC.0000000000001071","article-title":"Cost-effectiveness of thrombotic thrombocytopenic purpura diagnosis: a retrospective analysis in the University Hospital Center of Lyon (France)","volume":"33","author":"Jousselme","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.ekir.2024.09.004_bib153","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1111\/trf.14230","article-title":"ADAMTS13 test and\/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis","volume":"57","author":"Kim","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.ekir.2024.09.004_bib154","article-title":"Cost-effectiveness of frontline treatment for advanced renal cell carcinoma in the era of immunotherapies","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2024.09.004_bib155","article-title":"Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.ekir.2024.09.004_bib156","article-title":"Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy","volume":"11","author":"Aiello","year":"2023","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.ekir.2024.09.004_bib157","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/CEOR.S218464","article-title":"Budget impact analysis of subcutaneous Belimumab in patients with systemic lupus erythematosus in Spain","volume":"11","author":"Cevey","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib158","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/acr2.11177","article-title":"Evaluation of the economic benefit of earlier systemic lupus erythematosus (SLE) diagnosis using a multivariate assay panel (MAP)","volume":"2","author":"Clarke","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ekir.2024.09.004_bib159","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2019000827","article-title":"Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Goshua","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2024.09.004_bib160","first-page":"1171","article-title":"Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis","volume":"27","author":"Hutson","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib161","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/09612033221083270","article-title":"A\u00a0pharmacoeconomic study comparing the use of mycophenolate mofetil or cyclophosphamide as induction therapy in lupus nephritis patients in Egypt","volume":"31","author":"Khattab","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2024.09.004_bib162","first-page":"1664","article-title":"Comparison of renal cell carcinoma surveillance guidelines: competing trade-offs","volume":"195","author":"Lobo","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ekir.2024.09.004_bib163","first-page":"1441","article-title":"Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP)","volume":"23","author":"Massachi","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib164","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajmg.a.35718","article-title":"A\u00a0cost savings approach to SPRED1 mutational analysis in individuals at risk for neurofibromatosis type 1","volume":"161a","author":"Muram","year":"2013","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.ekir.2024.09.004_bib165","first-page":"1002","article-title":"Budget impact analysis of eliglustat for the treatment of Gaucher disease Type 1 in the United States","volume":"24","author":"Nalysnyk","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib166","first-page":"200","article-title":"Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US","volume":"18","author":"Perrin","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib167","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14737167.2023.2174972","article-title":"Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus","volume":"23","author":"Petrou","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib168","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1017\/S026646231600057X","article-title":"Budget impact analysis of Belimumab in treating systemic lupus erythematosus","volume":"32","author":"Pierotti","year":"2016","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ekir.2024.09.004_bib169","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1185\/03007995.2015.1081881","article-title":"Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients","volume":"31","author":"Racsa","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2024.09.004_bib170","first-page":"335","article-title":"The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma","volume":"24","author":"Swallow","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib171","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/1471-2407-13-399","article-title":"Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain","volume":"13","author":"Villa","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ekir.2024.09.004_bib172","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14737167.2022.2019017","article-title":"Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia","volume":"22","author":"Gil-Rojas","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib173","first-page":"291","article-title":"Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective","volume":"24","author":"Engel","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib174","first-page":"979","article-title":"Real-world treatment patterns and costs for patients with renal cell carcinoma initiating treatment with sunitinib and pazopanib","volume":"22","author":"MacLean","year":"2016","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib175","first-page":"1150","article-title":"Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China","volume":"21","author":"Shi","year":"2018","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib176","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40273-019-00824-2","article-title":"Rising economic burden of renal cell carcinoma among elderly patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data","volume":"37","author":"Shih","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ekir.2024.09.004_bib177","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.21873\/anticanres.13749","article-title":"Sunitinib first-line treatment in metastatic renal cell carcinoma: costs and effects","volume":"39","author":"Vuorinen","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ekir.2024.09.004_bib178","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12711","article-title":"Economic impact of a rapid, on-demand ADAMTS-13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura","volume":"6","author":"White","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.09.004_bib179","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10067-021-05900-7","article-title":"A\u00a04-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis","volume":"41","author":"Shenavandeh","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2024.09.004_bib180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/vox.12912","article-title":"Potential impact of a delayed ADAMTS13 result in the treatment of thrombotic microangiopathy: an economic analysis","volume":"115","author":"Kim","year":"2020","journal-title":"Vox Sang"},{"key":"10.1016\/j.ekir.2024.09.004_bib181","first-page":"1178","article-title":"Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective","volume":"24","author":"Pollissard","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.ekir.2024.09.004_bib182","first-page":"525","article-title":"Real-world economic outcomes during time on treatment among patients who initiated sunitinib or pazopanib as first targeted therapy for advanced renal cell carcinoma: a retrospective analysis of Medicare claims data","volume":"24","author":"Vogelzang","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ekir.2024.09.004_bib186","series-title":"Tolvaptan for treating autosomal dominant polycystic kidney disease","author":"Robert Wolff","year":"2015"},{"key":"10.1016\/j.ekir.2024.09.004_bib188","author":"Ana Kis"},{"key":"10.1016\/j.ekir.2024.09.004_bib191","article-title":"A\u00a0systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry\u2019s disease and mucopolysaccharidosis type 1","volume":"10:iii-113","author":"Connock","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ekir.2024.09.004_bib196","article-title":"The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review","volume":"11:iii-93","author":"Colquitt","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ekir.2024.09.004_bib198","author":"Nkrumah"},{"key":"10.1016\/j.ekir.2024.09.004_bib200","first-page":"137","article-title":"Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"37","author":"Montante","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2024.09.004_bib202","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ekir.2024.09.004_bib203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","article-title":"The national economic burden of rare disease in the United States in 2019","volume":"17","author":"Yang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib204","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-018-0936-x","article-title":"From scientific discovery to treatments for rare diseases - the view from the\u00a0National Center for Advancing Translational Sciences - Office of Rare Diseases Research","volume":"13","author":"Kaufmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2024.09.004_bib205","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/jpc.15507","article-title":"Rare diseases research and policy in Australia: on the journey to equitable care","volume":"57","author":"Bhattacharya","year":"2021","journal-title":"J\u00a0Paediatr Child Health"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:09:13Z","timestamp":1733216953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924019223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":185,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2468024924019223"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.09.004","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scoping Review of Economic Analyses of Rare Kidney Diseases","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}